Halozyme Therapeutics Inc
$ 70.73
0.33%
11 Jun - close price
- Market Cap 8,389,498,000 USD
- Current Price $ 70.73
- High / Low $ 71.12 / 70.26
- Stock P/E 24.82
- Book Value 1.85
- EPS 2.85
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.22 %
- ROE 0.99 %
- 52 Week High 82.22
- 52 Week Low 51.06
About
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Analyst Target Price
$83.90
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-17 | 2025-11-03 | 2025-08-05 | 2025-05-06 | 2025-02-18 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-06 | 2023-08-08 |
| Reported EPS | 1.2212 | -0.24 | 1.72 | 1.54 | 1.11 | 1.26 | 1.27 | 0.91 | 0.79 | 0.82 | 0.75 | 0.74 |
| Estimated EPS | 1.76 | 2.2 | 1.63 | 1.27 | 0.95 | 1.1588 | 0.98 | 0.76 | 0.7 | 0.83 | 0.71 | 0.64 |
| Surprise | -0.5388 | -2.44 | 0.09 | 0.27 | 0.16 | 0.1012 | 0.29 | 0.15 | 0.09 | -0.01 | 0.04 | 0.1 |
| Surprise Percentage | -30.6136% | -110.9091% | 5.5215% | 21.2598% | 16.8421% | 8.7332% | 29.5918% | 19.7368% | 12.8571% | -1.2048% | 5.6338% | 15.625% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.82 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HALO
2026-06-10 15:30:00
Halozyme Therapeutics (HALO) shares have increased by 0.8% since its last earnings report, outperforming the S&P 500. The company reported strong first-quarter 2026 results, with adjusted earnings of $1.60 per share and total revenues of $376.7 million, both surpassing Zacks Consensus Estimates. Despite a downward trend in recent estimate revisions, Halozyme maintains a Zacks Rank #3 (Hold) and strong growth prospects for 2026.
2026-06-09 20:40:26
Halozyme Therapeutics (HALO) Senior Vice President and Chief Financial Officer, Darren Snellgrove, has filed an initial Form 3 statement of beneficial ownership. This administrative filing establishes his insider status but reports no buy, sell, or derivative transactions. The document indicates that no securities are beneficially owned by Snellgrove at this time.
2026-06-09 04:39:52
Natixis Advisors LLC has reduced its stake in Halozyme Therapeutics by 13.1% in the fourth quarter, yet still holds 99,296 shares valued at $6.68 million. Despite this, analysts maintain a "Moderate Buy" consensus and increased price targets, with the company reporting strong quarterly results and positive FY2026 EPS guidance. However, recent insider selling by the CEO and COO has also been noted.
2026-06-07 15:09:47
Halozyme Therapeutics (HALO) has garnered fresh attention due to encouraging data from its partner argenx regarding a therapy using the ENHANZE delivery platform, alongside an analyst's reaffirmation of a positive stance. Despite steady share price gains and double-digit returns, the stock is considered 16.5% undervalued by analysts, with a fair value estimate of $85.78, though its current P/E ratio is higher than the industry average. The company's valuation is driven by anticipated growth from expanding partnerships and increased adoption of its subcutaneous biologics.
2026-06-06 20:39:10
This article provides financial information for Halozyme Therapeutics, Inc. (XETR:RV7), specifically focusing on its quick ratio. It presents a table showing period values, changes, and percentage changes related to this financial metric. The content appears to be a stub or a section from a larger financial data page on TradingView.
2026-06-06 13:39:10
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Halozyme Therapeutics, Inc., providing a detailed overview of each fund. The data includes market value, weight of Halozyme stock within the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify ETFs that offer exposure to Halozyme Therapeutics, Inc. with diversified portfolios.
